Hot Investor Mandate 2: Strategic Venture Fund of a Japanese Pharma Seeks to Invest in First-In-Class Therapeutics Opportunities, with Strong Focus in Oncology

29 Mar

A strategic corporate venture capital fund by a full-fledged oncology pharmaceutical company headquartered in Tokyo, Japan, seeks to make equity investment in startup companies that discover and develop innovative therapeutic products and/or drug-enabling platform technologies that demonstrate a clear potential to benefit cancer patients. Investment size can be flexible depending on the deal. The firm will also consider the option-type of investments and spin-outs, in addition to pure equity investments. The fund is currently seeking opportunities in the USA, Europe and Japan, the focus being mainly in USA and Europe.

The firm will consider early-stage (generally research to pre-IND) first-in-class/new biology-based approaches in drug discovery and innovative platform technologies for drug discovery, especially assets that have a strategic angle to the pharmaceutical’s pipeline. The firm considers a wide variety of modalities (biologics/oncolytic viruses and small molecules) as well as cell and gene therapy, on an opportunistic basis. The firm’s primary indication of interest is oncology, but the firm is also interested in immunology, allergy, musculoskeletal, and orphan indications.

While the firm is primarily focused on therapeutics, the firm may review technologies in medical device, diagnostic, or digital health sectors if there is a strong strategic alignment.

The firm is looking for teams with strong sector expertise. With the support of the pharmaceutical’s established expertise in the field of oncology product discovery and development, the firm will provide financial resources and company outreach to build strategic alliances to help translate novel research and high potential drug candidates into cornerstone products. The firm may request regional option or rights on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

w

Connecting to %s

%d bloggers like this: